## VCYT: Veracyte, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($39.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Prudential Financial Inc. Has $1 Million Position in Veracyte, Inc. $VCYT**
- Source: MarketBeat | 20251208T100921 | Bullish | Relevance: 97%
- Prudential Financial Inc. significantly increased its stake in Veracyte, Inc. (NASDAQ:VCYT) by 178.4% in Q2, acquiring 23,785 additional shares to own a total of 37,118 shares valued at approximately $1.00 million. Veracyte has outperformed quarterly expectations with $0.51 EPS versus an expected $0.32, and reported revenue of $131.9 million, a 13.8% increase year-over-year. Analysts currently hold a "Moderate Buy" consensus rating for the company, with an average price target of $45.43.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $48 | $40 | +20% |
| 2025-11-11 | Morgan Stanley | $40 | $28 | +43% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |
| 2025-11-11 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.13M) |
| Sells | 22 ($3.88M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 70.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 16.5% (+68.9%)
- Vanguard Group Inc: 10.8% (+5.0%)
- Artisan Partners Lim: 9.3% (+16.6%)
- FMR, LLC: 8.6% (-16.2%)
- ARK Investment Manag: 5.7% (+17.5%)

### Key Risks

1. High beta (1.83) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Momentum deterioration: MRS_10 falling (-8.9% 5d) with bearish MACD, trend may be turning.
3. Insider selling cluster: $3.9M in recent transactions.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.78 indicates undervaluation relative to growth. Balance sheet: strong liquidity (6.2x), low leverage (D/E 0.09). Analyst sentiment positive (2 raises, avg +31%). Insider selling cluster ($3.9M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.5B |
| Beta | 1.83 |
| 52W Range | $22.61 - $50.71 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.78 |
| Forward P/E | 27.3 |
| Current P/E | 26.6 |
| YoY Growth | -2.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.5% to -6.5% (-8.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.38x) but short-term weakness (below SMA20). RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.46% (CS: 4) | Weak |
| RSI_14 | 52.8 | Neutral |
| MACD Histogram | -0.40 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.375x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $43.84
- **Stop Loss:** $39.56 (9.8% risk)
- **Target:** $48.12 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 70
- **Position Value:** $3,068.80
- **Portfolio %:** 3.07%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-24 (Est: $0.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.32 | $0.51 | +59.5% |
| 2025Q2 | $0.30 | $0.44 | +48.5% |
| 2025Q1 | $0.20 | $0.31 | +51.3% |
| 2024Q4 | $0.26 | $0.36 | +40.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*